Novartis appoints global head of development

Promotes Timothy Wright to the role

Novartis has promoted Timothy Wright to global head, development of its Novartis Pharmaceuticals division.

Dr Wright joined the Swiss pharmaceutical firm in 2004 and most recently served as senior vice president and global head of translational sciences at Novartis Institutes for BioMedical Research (NIBR). His group included translational medicine, biomarker development, preclinical safety (toxicology), and drug metabolism and pharmacokinetics.

Previously, he worked for Pfizer Global Research and Development as the exploratory therapy area leader for inflammation. He also served as chief of the division of rheumatology and clinical immunology and as an endowed professor at the University of Pittsburgh.

Dr Wright has a biology degree from the University of Delaware and a medical degree from the Johns Hopkins University School of Medicine.

You may also like

Research & Development

Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness

The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production
Research & Development

Novartis bolsters kidney disease portfolio with Regulus Therapeutics acquisition

Through the acquisition, Novartis will gain access Regulus Therapeutics' oligonucleotide, farabursen, which is designed for the treatment of ADPKD
Manufacturing

Novartis to invest $23bn into US manufacturing and R&D capacity

The US investment will involve the construction of seven new manufacturing facilities, as well as a biomedical research innovation hub in San Diego
Finance

Novartis to acquire clinical-stage biopharma company, Anthos Therapeutics

Through the deal, Novartis will acquire Anthos' lead asset abelacimab, a fully human monoclonal anticoagulant designed to prevent stroke and systemic embolism in patients with atrial fibrillation
Finance

Calypso enters into agreement to be acquired by Novartis

The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastrointestinal and rheumatology indications
Research & Development

Intellegens secures $2m to support research of oligonucleotide therapeutic manufacture

In collaboration with CPI, Intellegens has secured a grant from Innovate UK to fund a two year project to augment technology that will assist productivity and yields of oligonucleotide therapeutic manufacture
Manufacturing

Novartis completes acquisition of precision medicine developer Chinook

Novartis has announced the acquisition of a US-based biopharmaceutical company focused on the discovery of precision medicines for kidney diseases named Chinook Therapeutics
Subscribe now